American Journal of Obstetrics & Gynecology
Volume 202, Issue 3 , Pages 255.e1-255.e7 , March 2010

Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia

Presented orally at the 30th Annual Meeting of the Society for Maternal-Fetal Medicine, Chicago, IL, Feb. 1-6, 2010.

  • Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group

Received 18 November 2009 ,Revised 21 December 2009 ,Accepted 14 January 2010.

References 

  1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–137
  2. Solomon CG, Seely EW. Hypertension in pregnancy: a manifestation of the insulin resistance syndrome?. Hypertension. 2001;37:232–239
  3. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab. 2003;88:2393–2398
  4. Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent pre-eclampsia: a prospective study. J Clin Endocrinol Metab. 2002;87:1563–1568
  5. Lorentzen B, Birkeland KI, Endresen MJ, Henriksen T. Glucose intolerance in women with pre-eclampsia. Acta Obstet Gynecol Scand. 1998;77:22–27
  6. Martinez AE, Gonzalez OM, Quinones GA, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with preeclampsia: a controlled study. Am J Hypertens. 1996;610–614
  7. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism. 1999;48:892–896
  8. Moran C, Sandoval T, Duque X, Gonzalez S, Moran S, Bermudez JA. Increased insulin levels independent of gestational overweight in women with preeclampsia. Arch Med Res. 2006;37:749–754
  9. Emery SP, Levine RJ, Qian C, et al. Twenty-four-hour urine insulin as a measure of hyperinsulinemia/insulin resistance before onset of pre-eclampsia and gestational hypertension. BJOG. 2005;112:1479–1485
  10. Sowers JR, Sokol RJ, Standley PR, et al. Insulin resistance and increased body mass index in women developing hypertension in pregnancy. Nutr Metab Cardiovasc Dis. 1996;6:141–146
  11. Thadani R, Stampfer MJ, Hunder DJ, Manson JE, Solomon CG, Curhan GC. High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94:543–550
  12. Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study: the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet GynecoI. 1995;172:642–648
  13. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women: the Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997;177:1003–1010
  14. Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Am J Obstet Gynecol. 1998;179:1032–1037
  15. Schmidt MI, Duncan BB, Reichelt AJ, et al. Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes. Diabetes Care. 2001;24:1151–1155
  16. Yogev Y, Xenakis EMJ, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol. 2004;191:1655–1660
  17. Nordin NM, Wei JWH, Naing NN, Symonds EM. Comparison of maternal-fetal outcomes in gestational diabetes and lesser degrees of glucose intolerance. J Obstet Gynaecol Res. 2006;32:107–114
  18. Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes: the Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol. 1995;173:146–156
  19. HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynecol Obstet. 2002;78:69–77
  20. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002
  21. Nesbitt GS, Smye M, Sheridan B, et al. Integration of local and central laboratory functions in a worldwide multicentre study: experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Clin Trials. 2006;3:397–407
  22. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:ix–xiv
  23. McIntyre HD, Chang AM, Callaway LK, et al. Hormonal and metabolic factors associated with variations in insulin sensitivity in human pregnancy. Diabetes Care. 2010;33:356–360
  24. World Health Organization. Obesity: preventing and managing a global epidemic. World Health Organ Tech Rep Ser. 2000;894:1–4
  25. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic review. Epidemiology. 2003;14:368–374
  26. Sierra-Laguado J, García RG, Celedón J, et al. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancy-induced hypertension. Am J Hypertens. 2007;20:437–442
  27. Parretti E, Lapolla A, Dalfra MG, et al. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension. 2006;47:449–453
  28. Srinivas SK, Sammel MD, Bastek J, et al. Evaluating the association between all components of the metabolic syndrome and pre-eclampsia. J Matern Fetal Neonatal Med. 2009;22:501–509
  29. Kaaja R, Laivuori H, Pulkki P, Tikkanen MJ, Hiilesmaa V, Ylikorkala O. Is there any link between insulin resistance and inflammation in established preeclampsia?. Metabolism. 2004;53:1433–1435
  30. Anim-Nyame N, Sooranna SR, Jones J, Alaghband-Zadeh J, Steer PJ, Johnson MR. Insulin resistance and pre-eclampsia: a role for tumor necrosis factor-alpha?. Gynecol Endocrinol. 2004;18:117–123
  31. Lykke JA, Langhoff-Ross J, Sibai B, Funai EF, Triche EW, Paides MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944–951
  32. IADPSG Consensus Panel. International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. In press.
  33. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352:2477–2486
  34. Landon M, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361:11–20

 Supported by from the National Institute of Child Health and Human Development and the National Institute of Diabetes, Digestive, and Kidney Diseases (Grants R01-HD34242 and R01-HD34243); the National Center for Research Resources (M01-RR00048, M01-RR00080); the American Diabetes Association; Diabetes UK (RD04/0002756); Kaiser Permanente Medical Center; KK Women's and Children's Hospital; Mater Mother's Hospital; Novo Nordisk; the Myre Sim Fund of the Royal College of Physicians of Edinburgh, and the Howard and Carol Bernick Family Foundation.

 The Writing Group takes responsibility for the content of this article. Members of the HAPO Study Cooperative Research Group are listed in the appendix of: HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcomes. N Engl J Med 2008;358:1991-2002.

 Cite this article as: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: preeclampsia. Am J Obstet Gynecol 2010;202:255.e1-7.

 The racing flag logo above indicates that this article was rushed to press for the benefit of the scientific community.

 Reprints: Boyd E. Metzger, MD, Northwestern University Feinberg School of Medicine, Endocrinology, 645 N Michigan Ave., Suite 530-22, Chicago, IL 60611.

 From the members of the Writing Group [Division of Maternal-Fetal Medicine, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petah-Tiqva, Israel (Drs Yogev, Chen, and Hod); the Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Alpert Medical School of Brown University, Providence, RI (Dr Coustan); the Diabetes Service, Royal Women's Hospital, Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia (Dr Oats); the Department of Endocrinology and Obstetric Medicine, Mater Health Services and Mater Clinical School of Medicine, University of Queensland, Brisbane, QLD, Australia (Dr McIntyre); the Division of Endocrinology, Department of Medicine (Dr Metzger), the Department of Preventive Medicine (Drs Lowe and Dyer), and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology (Dr Dooley), Northwestern University Feinberg School of Medicine, Chicago, IL; the Diabetes Research Group, Queen's University Belfast (Dr Trimble), the Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital (Dr McCance), and the Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, and Royal Jubilee Maternity Hospital and Queen's University Belfast (Dr Hadden), Belfast, UK; the Department of Women and Child Health, Karolinska Institute, Stockholm, Sweden (Dr Persson); and the Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong, People's Republic of China (Dr Rogers)].

PII: S0002-9378(10)00035-9

doi: 10.1016/j.ajog.2010.01.024

American Journal of Obstetrics & Gynecology
Volume 202, Issue 3 , Pages 255.e1-255.e7 , March 2010

Article Tools